Cancer-specific delivery of bacterium
EP4598555A1Inactive Publication Date: 2025-08-13PAN CHONG XIAN
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- EP2023802048
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-06
- Filing Date
- 2023-10-05
- Publication Date
- 2025-08-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Current methods for delivering therapeutic or diagnostic agents to cancer sites are inefficient, often requiring parenteral administration and facing challenges with stability and specificity, while also risking non-specific toxicity.
Method used
Oral administration of genetically engineered tumor-targeting bacteria, such as Salmonella or Listeria, equipped with tumor-targeting peptides or proteins that specifically guide them to cancer sites, allowing for targeted delivery of therapeutic or diagnostic agents.
Benefits of technology
Achieves high concentration of therapeutic agents at tumor sites with enhanced specificity and stability, reducing non-specific toxicity and enabling effective cancer treatment while being cost-effective and straightforward to produce.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 1.1
Abstract
The present invention provides a method of delivering a tumor-targeting bacterium to a tumor site in an individual having cancer, comprising orally administering to the individual an effective amount of the tumor-targeting bacterium or bacteria. The tumor-targeting bacterium comprises on its surface a tumor-targeting agent so that upon administration the tumor-targeting bacterium is specifically targeted to the tumor site. The tumor-targeting bacterium can be used for treating cancer, or for the purpose of delivering therapeutic or diagnostic agents to a tumor site.
Need to check novelty before this filing date? Find Prior Art